Founded in 1980 by Thomas J. McKearn and based in Princeton, New Jersey, Cytogen has a portfolio of pharmaceutical products for cancer treatment, including QUADRAMET, PROSTASCINT, CAPHOSOL, and SOLTAMOX. They are also developing CYT-500, a radiolabeled antibody for prostate cancer. In 2008, Cytogen was acquired by EUSA Pharma. Their specialized sales force markets these products, which address various aspects of cancer care, such as metastatic bone pain, prostate cancer imaging, and oral mucositis and dry mouth during chemotherapy.